PHS
BCRX icon

PFM Health Sciences’s BioCryst Pharmaceuticals BCRX Stock Holding History

PFM Health Sciences’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-550,000
Closed -$5.82M – 88
2022
Q2 		$5.82M Buy
+550,000
New +$5.67M 0.22% 72

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PFM Health Sciences's BCRX Position: Q2 2023 in Review

PFM Health Sciences sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 2,162,411 shares — an estimated $18M sold.

PFM Health Sciences first reported a position in BCRX in Q2 2021 and held it in 5 quarters. The position peaked at $27.2M in Q3 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • PFM Health Sciences reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • PFM Health Sciences sold 2,162,411 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $18M.
  • PFM Health Sciences first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • PFM Health Sciences's BioCryst Pharmaceuticals position peaked at $27.2M in Q3 2022.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.